{"schema_version":"secwatch.filing_event.v1","accession":"0001999371-26-010487","form_type":"8-K","ticker":"TNXP","cik":"0001430306","company_name":"Tonix Pharmaceuticals Holding Corp.","filed_at":"2026-05-11T21:17:22+00:00","discovered_at":"2026-05-11T21:18:00.334183+00:00","generated_at":"2026-05-11T21:19:15.814309+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Tonix Q1 net loss $40.2M; TONMYA launch generates $3.7M revenue with 2,145 prescribers","bullets":["Net product revenue $6.9M (TONMYA $3.7M, legacy products $3.2M); net loss $40.2M ($2.93/share).","Cash $185.5M at Mar 31; raised $22.6M post-quarter via ATM; runway into early Q2 2027.","TONMYA Q1: 2,145 HCPs prescribed, 3,588 patients initiated, ~5,400 Rx; cumulative 11,016 Rx through May 1.","Secured GPO agreement covering ~35M commercial lives; Medicaid coverage in 38 states (~55M lives).","TNX-4800 Phase 2 Lyme prevention study planned for 2027; TNX-102 SL MDD Phase 2 to start mid-2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001999371-26-010487","json":"https://secwatch.observer/filing/0001999371-26-010487.json","markdown":"https://secwatch.observer/filing/0001999371-26-010487.md","text":"https://secwatch.observer/filing/0001999371-26-010487.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1430306/000199937126010487/0001999371-26-010487-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1430306/000199937126010487/tnxp-8k_051126.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-11T21:19:15.814309+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ff0117ec124015eb727910ad04a7cc507da65623","claim":"Tonix Pharmaceuticals Holding Corp. reported financial results for the quarter ended March 31, 2026.","evidence_excerpt":"On May 11, 2026, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced its operating results for the quarter ended March 31, 2026. A copy of the press release that discusses these matters is filed as Exhibit 99.01 to, and incorporated by reference in, this report.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1430306/000199937126010487/0001999371-26-010487-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}